Compare Stocks: SHLT, INO, RFL, and APYX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APYX Apyx Medical	$3.05 -1.0%	$3.87	$1.70 ▼ $5.08	$128.47M	1.39	144,722 shs	46,726 shs
INO Inovio Pharmaceuticals	$1.27 -1.6%	$1.05	$0.56 ▼ $2.98	$131.32M	1.52	2.56 million shs	5.62 million shs
RFL Rafael	$2.55 -0.4%	$2.33	$1.12 ▼ $3.96	$132.60M	0.33	127,457 shs	98,074 shs
SHLT SHL Telemedicine	$2.05	$2.05	$1.85 ▼ $4.45	$33.61M	0.11	11,919 shs	N/A

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APYX Apyx Medical	0.00%	-1.28%	-24.88%	-22.22%	+54.77%
INO Inovio Pharmaceuticals	0.00%	+9.32%	+90.55%	+0.78%	-45.57%
RFL Rafael	0.00%	+16.67%	+29.23%	+82.61%	+70.85%
SHLT SHL Telemedicine	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APYX Apyx Medical	$3.05 -1.0%	$3.87	$1.70 ▼ $5.08	$128.47M	1.39	144,722 shs	46,726 shs
INO Inovio Pharmaceuticals	$1.27 -1.6%	$1.05	$0.56 ▼ $2.98	$131.32M	1.52	2.56 million shs	5.62 million shs
RFL Rafael	$2.55 -0.4%	$2.33	$1.12 ▼ $3.96	$132.60M	0.33	127,457 shs	98,074 shs
SHLT SHL Telemedicine	$2.05	$2.05	$1.85 ▼ $4.45	$33.61M	0.11	11,919 shs	N/A

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APYX Apyx Medical	0.00%	-1.28%	-24.88%	-22.22%	+54.77%
INO Inovio Pharmaceuticals	0.00%	+9.32%	+90.55%	+0.78%	-45.57%
RFL Rafael	0.00%	+16.67%	+29.23%	+82.61%	+70.85%
SHLT SHL Telemedicine	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APYX Apyx Medical	2.71	Moderate Buy	$6.60	116.39% Upside
INO Inovio Pharmaceuticals	2.75	Moderate Buy	$3.17	149.34% Upside
RFL Rafael	1.00	Sell	N/A	N/A
SHLT SHL Telemedicine	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SHLT, INO, RFL, and APYX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	RFL Rafael	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/13/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	INO Inovio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/13/2026	INO Inovio Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Positive	$1.80 ➝ $3.00
8/12/2026	INO Inovio Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/3/2026	INO Inovio Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$4.00
7/29/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/14/2026	APYX Apyx Medical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/13/2026	APYX Apyx Medical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
7/1/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	APYX Apyx Medical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APYX Apyx Medical	$52.84M	2.43	N/A	N/A	$0.39 per share	7.82
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	$0.36 per share	N/A
RFL Rafael	$920K	144.13	N/A	N/A	$1.91 per share	1.34
SHLT SHL Telemedicine	$55.94M	0.60	$0.04 per share	54.03	$5.21 per share	0.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APYX Apyx Medical	-$11.21M	-$0.20	N/A	N/A	N/A	-14.78%	-76.60%	-13.91%	11/5/2026 (Estimated)
INO Inovio Pharmaceuticals	-$84.95M	-$0.91	N/A	N/A	N/A	N/A	-669.94%	-73.97%	11/10/2026 (Estimated)
RFL Rafael	-$30.52M	-$0.68	N/A	N/A	N/A	-3,321.74%	-41.27%	-35.32%	10/28/2026 (Estimated)
SHLT SHL Telemedicine	-$7.06M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest SHLT, INO, RFL, and APYX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2026	Q2 2026	INO Inovio Pharmaceuticals	-$0.2167	-$0.07	+$0.1467	-$0.07	$0.53 million	N/A
8/6/2026	Q2 2026	APYX Apyx Medical	-$0.0820	-$0.07	+$0.0120	-$0.07	$13.18 million	$13.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APYX Apyx Medical	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RFL Rafael	N/A	N/A	N/A	N/A	N/A
SHLT SHL Telemedicine	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APYX Apyx Medical	3.19	5.68	4.53
INO Inovio Pharmaceuticals	N/A	1.00	1.00
RFL Rafael	N/A	3.16	3.14
SHLT SHL Telemedicine	0.19	2.17	1.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APYX Apyx Medical	55.33%
INO Inovio Pharmaceuticals	26.79%
RFL Rafael	11.30%
SHLT SHL Telemedicine	20.11%

Insider Ownership

Company	Insider Ownership
APYX Apyx Medical	15.90%
INO Inovio Pharmaceuticals	1.70%
RFL Rafael	32.90%
SHLT SHL Telemedicine	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APYX Apyx Medical	270	42.12 million	35.43 million	Optionable
INO Inovio Pharmaceuticals	320	103.40 million	101.64 million	Optionable
RFL Rafael	20	52.00 million	34.89 million	Optionable
SHLT SHL Telemedicine	583	16.39 million	N/A	Not Optionable

SHLT, INO, RFL, and APYX Headlines

Recent News About These Companies

SHL Telemedicine Ltd American Depositary Shares (SHLT)

April 3, 2026 | nasdaq.com

SHL Telemedicine ADR Stock Price History

June 20, 2025 | investing.com

SHL Telemedicine Clarifies Voting Process for May 2025 AGM

May 20, 2025 | tipranks.com

SHL Telemedicine to Delist ADRs from Nasdaq to Cut Costs

March 11, 2025 | tipranks.com

SHLT SHL Telemedicine Ltd.

March 6, 2025 | seekingalpha.com

SHL Telemedicine Ltd (SHLTN)

January 23, 2025 | investing.com

SHL Telemedicine (NASDAQ:SHLT) Stock Quotes, Forecast and News Summary

December 18, 2024 | benzinga.com

DocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular Care

December 18, 2024 | businesswire.com

SHL Telemedicine (NASDAQ:SHLT) Stock, Short Interest Report

October 9, 2024 | benzinga.com

SHL Telemedicine to Appoint David Arnon as CEO of SHL Telemedicine

July 29, 2024 | 01net.it0

SHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli Activity

June 20, 2024 | businesswire.com

SHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood Test

May 21, 2024 | businesswire.com

SHL Telemedicine Ltd ADR - New

May 17, 2024 | morningstar.comM

SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch

May 16, 2024 | finance.yahoo.com

SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch

May 16, 2024 | businesswire.com

SHL Telemedicine Ltd.: SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones

April 17, 2024 | finanznachrichten.de

SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones

April 17, 2024 | finance.yahoo.com

SHL Telemedicine Ltd. (SHLT)

April 16, 2024 | finance.yahoo.com

Telehealth clinical trial cuts hospital cardiac readmissions by 76%

April 11, 2024 | msn.com

Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine’s SmartHeart® in Post-ACS Patient Care

April 11, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SHLT, INO, RFL, and APYX Company Descriptions

Apyx Medical NASDAQ:APYX

$3.05 -0.03 (-0.97%)

As of 04:00 PM Eastern

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Inovio Pharmaceuticals NASDAQ:INO

$1.27 -0.02 (-1.55%)

As of 04:00 PM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Rafael NYSE:RFL

$2.55 -0.01 (-0.39%)

As of 03:58 PM Eastern

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

SHL Telemedicine NASDAQ:SHLT

SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; and Cardio'B, a portable device to transmit a 12-lead ECG. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices, including blood pressure, weighing, oxygen saturation level (TelePulse Oximeter), breath exhalation (TeleBreather), and sugar measuring devices; and TelePress, a remote blood pressure monitoring device for personal use. It offers its telemedicine services and devices to subscribers using electronic and telecommunication technologies. The company serves physicians, hospitals, health insurance funds, and patients. It has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and the Hebrew University of Jerusalem and the Hadassah Medical Center. The company was incorporated in 1986 and is headquartered in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SHLT, INO, RFL, and APYX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SHLT, INO, RFL, and APYX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SHLT, INO, RFL, and APYX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SHLT, INO, RFL, and APYX Company Descriptions

Apyx Medical NASDAQ:APYX

Inovio Pharmaceuticals NASDAQ:INO

Rafael NYSE:RFL

SHL Telemedicine NASDAQ:SHLT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SHLT, INO, RFL, and APYX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SHLT, INO, RFL, and APYX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SHLT, INO, RFL, and APYX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SHLT, INO, RFL, and APYX Company Descriptions

Apyx Medical NASDAQ:APYX

Inovio Pharmaceuticals NASDAQ:INO

Rafael NYSE:RFL

SHL Telemedicine NASDAQ:SHLT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools